drugset / Trial / NCT00614731

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

NCT00614731

RandomizedParallel-groupOpen-labelBasic science

Summary

Atopic dermatitis (AD) is a skin disorder in which people often have swelling and skin infections. People with this disease cannot receive the smallpox vaccine because it could cause them to have a fatal reaction known as eczema vaccinatum (EV). Keyhole limpet hemocyanin (KLH) is a protein that can be used to deliver vaccines to the body. The purpose of this study is to determine a baseline immune reaction to KLH in people without AD. Once this has been established, other studies can be designed to determine whether KLH can be used to give vaccines to people with AD.

Timeline

Start
2007-12
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject keyhole limpet hemocyanin Vaccine 50 ug Intravenous
Subject keyhole limpet hemocyanin Vaccine 100 ug Intravenous
Subject keyhole limpet hemocyanin Vaccine 250 ug Intravenous
Subject keyhole limpet hemocyanin Vaccine 1 mg/ml Intravenous
Subject keyhole limpet hemocyanin Vaccine 10 mg/ml Intravenous
Subject keyhole limpet hemocyanin Vaccine 20 mg/ml Intravenous

Indications